Hims & Hers Health, Inc. $HIMS Shares Bought by FirstWave Capital Management LLC

FirstWave Capital Management LLC increased its position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 30.6% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 339,978 shares of the company’s stock after buying an additional 79,731 shares during the period. Hims & Hers Health accounts for 5.2% of FirstWave Capital Management LLC’s holdings, making the stock its 5th biggest holding. FirstWave Capital Management LLC’s holdings in Hims & Hers Health were worth $11,787,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of HIMS. MassMutual Private Wealth & Trust FSB grew its holdings in Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares during the period. Sigma Planning Corp lifted its stake in shares of Hims & Hers Health by 1.5% in the 1st quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock valued at $540,000 after purchasing an additional 388 shares during the period. Captrust Financial Advisors boosted its position in shares of Hims & Hers Health by 3.1% during the 2nd quarter. Captrust Financial Advisors now owns 14,612 shares of the company’s stock valued at $728,000 after purchasing an additional 443 shares in the last quarter. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health during the 3rd quarter valued at about $28,000. Finally, Northwestern Mutual Investment Management Company LLC grew its stake in Hims & Hers Health by 1.1% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 46,607 shares of the company’s stock worth $1,513,000 after purchasing an additional 521 shares during the period. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 0.6%

Shares of Hims & Hers Health stock opened at $27.66 on Friday. The stock has a market capitalization of $6.45 billion, a PE ratio of -43.90 and a beta of 2.42. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $65.30. The stock has a 50 day moving average price of $31.67 and a two-hundred day moving average price of $26.75. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period in the previous year, the company earned $0.17 earnings per share. Hims & Hers Health’s revenue for the quarter was up 38.2% compared to the same quarter last year.

Analyst Upgrades and Downgrades

HIMS has been the topic of several recent analyst reports. BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Needham & Company LLC raised their price objective on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Barclays lowered their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research note on Friday, August 21st. Truist Financial increased their target price on shares of Hims & Hers Health from $27.00 to $32.00 and gave the stock a “hold” rating in a research note on Monday, August 24th. Finally, Bank of America raised their price target on shares of Hims & Hers Health from $30.00 to $32.00 and gave the stock a “neutral” rating in a report on Tuesday, August 11th. Four equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health has a consensus rating of “Hold” and an average price target of $32.50.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Patrick Carroll sold 23,726 shares of the business’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $35.00, for a total transaction of $830,410.00. Following the completion of the sale, the insider directly owned 181,861 shares of the company’s stock, valued at $6,365,135. The trade was a 11.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Deborah Autor sold 16,773 shares of the business’s stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $27.85, for a total value of $467,128.05. Following the sale, the insider directly owned 48,961 shares of the company’s stock, valued at $1,363,563.85. This represents a 25.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 190,227 shares of company stock worth $6,133,613 in the last ninety days. 11.76% of the stock is currently owned by corporate insiders.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers continues to show strong top-line momentum: second-quarter revenue rose 38.2% year over year to $753.2 million and exceeded analyst expectations. The company also raised its 2026 revenue outlook, supported by weight-loss treatments, international expansion and artificial-intelligence initiatives. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
• Neutral Sentiment: Analyst sentiment remains cautious. The consensus rating is “Hold,” with analysts recognizing the company’s growth opportunities while citing profitability pressure and uncertainty related to regulatory oversight.
• Negative Sentiment: Several investor-rights firms announced or promoted a securities-fraud class action against Hims & Hers and certain executives. The case covers investors who acquired securities between August 4, 2025, and July 29, 2026; investors must move for lead-plaintiff status by November 2, 2026. The repeated announcements increase concerns about potential legal expenses, penalties, management distraction and reputational damage. Rosen Law Firm HIMS Class Action Announcement
• Negative Sentiment: The litigation is tied to allegations stemming from an FTC complaint, including potentially deceptive privacy and billing practices. Claims that consumer health information may have been shared with advertising platforms and that customers may have been charged soon after submitting prescription-intake forms create risks of enforcement actions and additional compliance costs. These claims remain allegations. Kessler Topaz HIMS Investor Alert
• Negative Sentiment: Insider Soleil Boughton sold 3,458 shares for approximately $98,000 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s holdings by about 1.1%, making it a relatively small and scheduled sale, but it adds a modest negative signal amid the broader legal uncertainty. Hims & Hers Insider Sale

Hims & Hers Health Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.